Evidence map›Paper›PMID 27815263›Full record

ArticleBlood2016

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Bing Cui, Emanuela M Ghia, Liguang Chen, Laura Z Rassenti, Christopher DeBoever, George F Widhopf, Jian Yu, Donna S Neuberg, William G Wierda, Kanti R Rai and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Insulin-like growth factor receptor signaling in physiology and disease.Signal transduction and targeted therapy · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 3 countries.

Bing CuiDepartment of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, CA.
Emanuela M GhiaDepartment of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, CA.
Liguang ChenDepartment of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, CA.
Laura Z RassentiDepartment of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, CA.
Christopher DeBoeverBioinformatics and Systems Biology, University of California, San Diego, San Diego, CA.ORCID 0000-0002-1901-2576
George F WidhopfDepartment of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, CA.
Jian YuDepartment of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, CA.
Donna S NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard University, Boston, MA.ORCID 0000-0003-2566-3145
William G WierdaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Kanti R RaiDepartment of Medicine, Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, NY.ORCID 0000-0002-5804-2823
Neil E KayDepartment of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-5951-5055
Jennifer R BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA.
Jeffrey A JonesDivision of Hematology and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
John G GribbenDepartment of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK; and.
Kelly A FrazerMoores Cancer Center, Department of Pediatrics and Rady Children's Hospital, Institute for Genomic Medicine, Chronic Lymphocytic Leukemia Research Consortium, University of California, San Diego, San Diego, CA.ORCID 0000-0002-6060-8902
Thomas J KippsDepartment of Medicine, Moores Cancer Center, University of California, San Diego, San Diego, CA.
University of California San Diego · USHarvard University · USChinese Academy of Medical Sciences & Peking Union Medical College · CNHofstra University · USMayo Clinic in Arizona · USQueen Mary University of London · GBThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
Training Program in Basic Clinical GeneticsT32GM008666 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAMILTON, BRUCE A · 1998 to 2021
$8.6M
ANTIBODY V GENE EXPRESSION IN B CELL CLLR37CA049870 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 1994 to 2013
$4.5M
NCI NIH HHS P01 CA081534NCI NIH HHS P30 CA023100NCI NIH HHS R37 CA049870NIGMS NIH HHS T32 GM008666
6 · The paper itself

Abstract

ROR1 is an oncoembryonic orphan receptor found on chronic lymphocytic leukemia (CLL) B cells, but not on normal postpartum tissues. ROR1 is a receptor for Wnt5a that may complex with TCL1, a coactivator of AKT that is able to promote development of CLL. We found the CLL cells of a few patients expressed negligible ROR1 (ROR1

Indexed as

Disease ProgressionCell MovementCell ProliferationCell SurvivalDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, LeukemicGene Regulatory NetworksHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionLeukemia, Lymphocytic, Chronic, B-CellMultivariate AnalysisReceptor Tyrosine Kinase-like Orphan ReceptorsImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, human

Identifiers

PMID27815263
PMCPMC5179332
OpenAlexW2547412310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.